Study Title
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week
Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in
Patients with Diabetic Gastroparesis
Purpose
Extension study for RLM-MD-02 participants. To compare the efficacy of relamorelin with placebo in participants after 12 weeks of treatment. Total of 24 weeks (12 weeks from RLM-MD-02 study and 12 weeks from this study)
Eligibility
Study Process
Trial Details
Investigator:
IRB:
Copernicus
IRB Number:
Trial Type:
Drug
Sponsor:
Allergan
Contact Information: